Data analysis using logistic regression, ROC curves, and multivariate ANOVA demonstrated that the combination of alleles *04 of the HLA-DRB1 and *27 of the HLA-B with alleles (genotypes) of 11 non-HLA genes and clinical parameters (patient age, intensity, and duration of RA at the time of inclusion in the study) has more prominent association with response to olokizumab, if using ACR20 at week 24 as the response criterion. Here, HLA-DRB1 is linked to rheumatoid arthritis.